 |
 |
|
| |
ALDAGEN is a biotechnology company advancing a pipeline of clinical-stage regenerative therapies. The Company has three product candidates in clinical development for chronic heart failure, critical limb ischemia and pediatric metabolic disorders and malignancies. ALDAGEN's therapeutics are produced by a proprietary technology platform that selects potent, adult stem and progenitor cells for therapeutic use. The platform yields a broad range of therapeutic cells that can be used rapidly, without culture or expansion.
- Chronic heart failure clinical trial. [Click here]
- Critical limb ischemia clinical trial. [Click here] |
|
4.23.08
Aldagen Secures $18.4 Million in Financing
4.15.08
Initiation of ALD-101 Phase III Trial for
Improving Cord Blood Transplants ...
|
